Hjem › Blærecancer › Arizona › Tucson
Blærecancer kliniske forsøg i Tucson, AZ
5 studier for Blærecancer søger deltagere på steder i og omkring Tucson (inden for ca. 30 miles). Åbn et studie for at se, hvem der kan deltage, og hvordan man kontakter studieteamet.
Officiel studietekst (engelsk)
Rekrutterer til et studie her? Få det vist øverst på siden — $99 i 30 dage →
Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial
RekruttererFase 2
- Banner University Medical Center - Tucson, Tucson
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
RekruttererFase 3
- The University of Arizona Cancer Center - North Campus, Tucson
Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors
RekruttererFase 1/2
- Arizona Cancer Center at UMC North/University Medical Center, Tucson
FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
RekruttererFase 1
- University of Arizona - Cancer Center, Tucson
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
RekruttererFase 1
- The University of Arizona Cancer Center, Tucson
Blærecancer forsøg i andre byer
- New York City, NY35 studier
- Nashville, TN31 studier
- Houston, TX31 studier
- Dallas, TX27 studier
- Boston, MA26 studier
- Washington, DC26 studier
- Los Angeles, CA24 studier
- Baltimore, MD24 studier
- St. Louis, MO22 studier
- Philadelphia, PA21 studier
- Seattle, WA21 studier
- Edison, NJ21 studier
Andre studier i Tucson
- Brystkræft20 studier
- Ikke-småcellet lungecancer17 studier
- Overvægt17 studier
- Overvægt15 studier
- Metastatisk cancer14 studier
- Kræft (alle typer)12 studier
- Kardiovaskulær sygdom12 studier
- Colorektal kræft11 studier
- Prostatakræft11 studier
- Steatotisk leversygdom10 studier
- Hjertesvigt10 studier
- Højt blodtryk10 studier
Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.